Sadia MINHAS, Aneequa SAJJAD, Rabia Mushtaq CHAUDHRY, Hamza ZAHID, Azfar SHAHID, Muhammad KASHIF

Assessment and prevalence of concomitant chemo-radiotherapy-induced oral mucositis in patients with oral squamous cell carcinoma

Background/aim: Quantification of oral mucositis that progresses during concomitant chemo-radiotherapy (CCRT) is essential for its management. It is important to determine the methods that are simple, reliable and beneficial in foreseeing mucositis at earlier stages of treatment. Materials and methods: A prospective study was conducted on 100 oral cancer patients receiving CCRT following the inclusion criteria. Patients were evaluated for mucositis i.e. erythema and ulcers by using the World Health Organization (WHO) scale and the oral mucositis assessment scale (OMAS), whereas mature and immature cells were identified by exfoliative cytology. Clinical examination and procedure of oral cavity were performed before, on days 5, 17, and at the end of treatment. Results: Oral mucositis was observed in all oral squamous cell carcinoma (OSCC) patients receiving CCRT on different days with noteworthy increase from day 5 of CCRT to the end of treatment. For OMAS grading related to ulceration and erythema, Grade 1 (7.2%; 34%) was most commonly seen on the 5th day of CCRT, Grade 2 (29%; 19%) and Grade 3 (19%) were most frequently seen at the 17thday and end of CCRT, accordingly. With respect to WHO scale grades 1 and 2 (18.3%; 21.5%) was most frequently observed at the 17th day of CCRT, whereas grades 3 and 4 (12.5%; 2%) was noted at the end of CCRT. There was statistically significant increase in the percentage of immature cells at the end of CCRT (99%). A significant association (P < 0.0000) was observed among the days of smear and maturation stages of epithelial cells as well as among WHO mucositis grading, OMAS and types of epithelial cells, respectively. Conclusion: According to the findings of the study, oral mucositis grade is directly proportional to the progressing days of CCRT. Oral mucositis is frequently related to adverse clinical outcomes, affecting the patient’s quality of life. It is essential to develop methods that can be employed for the assessment of CCRT associated oral mucositis.Key words: Oral cancer, oral mucositis, CCRT, OMAS scale, exfoliative cytology

PDF

___

1. Wilkes JD. Prevention and treatment of oral mucositis following cancer chemotherapy. Seminars in Oncology 1998; 25 (5): 538-551. PMID: 9783593.
2. Chen SC, Lai YH, Huang BS, Lin CY, Fan KH et al. Changes and predictors of radiation-induced oral mucositis in patients with oral cavity cancer during active treatment. European Journal of Oncology Nursing 2015; 19 (3): 214-219. doi: 10.1016/j. ejon.2014.12.001
3. Naidu MU, Ramana GV, Rani PU, Mohan IK, Suman A et al. Chemotherapy-induced and/or radiation therapy-induced oral mucositis—complicating the treatment of cancer. Neoplasia 2004; 6 (5): 423-431. doi: 10.1593/neo.04169
4. Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M et al. Perspectives on cancer therapy‐induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 2004; 100 (9): 1995-2025. doi: 10.1002/ cncr.20162
5. Parulekar W, Mackenzie R, Bjarnason G, Jordan RC. Scoring oral mucositis. Oral Oncology 1998; 34 (1): 63-71. doi: 10.1016/ s1368-8375(97)00065-1
6. Trotti A. Toxicity in head and neck cancer: a review of trends and issues. International Journal of Radiation Oncology Biology Physics 2000; 47 (1): 1-2. doi: 10.1016/s0360-3016(99)00558-1
7. De Mendonça RMH, De Araújo M, Levy CE, Morari J, Silva RA et al. Prospective evaluation of HSV, Candida spp., and oral bacteria on the severity of oral mucositis in pediatric acute lymphoblastic leukemia. Supportive Care in Cancer 2012; 20 (5): 1101-1107. doi: 10.1007/s00520-011-1190-0
8. Sonis ST. Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncology 1998; 34 (1): 39-43. doi: 10.1016/s1368- 8375(97)00053-5
9. Berger AM, Kilroy TJ. Oral complications: Principles and Practice of Oncology. DeVita VJ Jr, Hellmen S, Rosenberg SA.1997: 2714.
10. Verdi CJ. Cancer therapy and oral mucositis. Drug Safety 1993; 9 (3): 185-195. doi: 10.2165/00002018-199309030-00004
11. Bensadoun RJ, Magné N, Marcy PY, Demard F. Chemotherapyand radiotherapy-induced mucositis in head and neck cancer patients: new trends in pathophysiology, prevention and treatment. European Archives of Oto-rhino-laryngology 2001; 258 (9): 481-487. doi: 10.1007/s004050100368
12. Fu KK, Phillips TL, Silverberg IJ, Jacobs C, Goffinet DR et al. Combined radiotherapy and chemotherapy with bleomycin and methotrexate for advanced inoperable head and neck cancer: update of a Northern California Oncology Group randomized trial. Journal of Clinical Oncology 1987; 5 (9): 1410-1418. doi: 10.1200/JCO.1987.5.9.1410
13. Kumari R, Chaugule A, Goyal PK. Karyoanomalic frequency during radiation therapy. Journal of Cancer Research and Therapeutics 2005; 1 (3): 187-190. doi: 10.4103/0973- 1482.19604
14. Umiker W, Lampe I, Rapp R, Latourette H, Boblitt D. Irradiation effects on malignant cells in smears from oral cancers. Cancer 1959; 12 (3): 614-619. doi: 10.1002/1097-0142(195905/06)12:3<614::aidcncr2820120322>3.0.co;2-x
15. Sonis ST. A comparison and assessment of scoring scales for mucositis. In: Oral Mucositis. Tarporley, England: Springer Healthcare; 2012. pp. 39-46. doi: 10.1007/978-1-907673-46- 7_6
16. Rajesh VL, Stephen TS, Douglas EP. Management of oral mucositis in patients with cancer. Dental Clinics of North America 2008; 52 (1): 61-68. doi: 10.1016/j.cden.2007.10.002
17. Sonis ST, Eilers JP, Epstein JB, LeVeque FG, Liggett Jr WH et al. Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Cancer 1999; 85 (10): 2103-2113. doi: 10.1002/ (sici)1097-0142(19990515)85:10<2103::aid-cncr2>3.0.co;2-0
18. Garden AS, Morrison WH, Wong PF, Tung SS, Rosenthal DI et al. Disease-control rates following intensity-modulated radiation therapy for small primary oropharyngeal carcinoma. International Journal of Radiation Oncology Biology Physics 2007; 67 (2): 438-444. doi: 10.1016/j.ijrobp.2006.08.078
19. Ahmed HG, Elemirri DA. Assessment of oral cytological changes associated with exposure to chemotherapy and/ or radiotherapy. Cytology Journal 2009; 6 (1): 8-13. doi: 10.4103/1742-6413.51332
20. Pereira IF, Firmino RT, Meira HC, Vasconcelos BC, Noronha VR et al. Radiation-induced oral mucositis in Brazilian patients: prevalence and associated Factors. In Vivo 2019; 33 (2): 605-609. (doi: 10.21873/invivo.11517)
21. De Sanctis V, Bossi P, Sanguineti G, Trippa F, Ferrari D et al. Mucositis in head and neck cancer patients treated with radiotherapy and systemic therapies: literature review and consensus statements. Critical Reviews in Oncology/Hematology 2016; 100: 147-166. doi: 10.1016/j. critrevonc.2016.01.010
22. Nicolatou-Galitis O, Kouloulias V, Sotiropoulou-Lountou A, Dardoufas K, Polychronopoulou AP et al. Oral mucositis, pain and xerostomia in 135 head and neck cancer patients receiving radiotherapy with or without chemotherapy. The Open Cancer Journal 2011; 4 (1): 7-17. doi: 10.2174/1874079001104010007
23. Wuketich S, Hienz SA, Marosi C. Prevalence of clinically relevant oral mucositis in outpatients receiving myelosuppressive chemotherapy for solid tumors. Supportive Care in Cancer 2012; 20 (1): 175-183. doi: 10.1007/s00520-011-1107-y
24. Vera Llonch M, Oster G, Hagiwara M, Sonis S. Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma: risk factors and clinical consequences. Cancer 2006; 106 (2): 329-336. doi: 10.1002/cncr.21622
25. Rosenthal DI. Consequences of mucositis-induced treatment breaks and dose reductions on head and neck cancer treatment outcomes. The Journal of Supportive Oncology 2007; 9 (4): 23-31. PMID: 18046995.
26. Jensen SB, Peterson DE. Oral mucosal injury caused by cancer therapies: current management and new frontiers in research. Journal of Oral Pathology & Medicine 2014; 43 (2): 81-90. doi. org/10.1111/jop.12135
27. Harada K, Ferdous T, Horinaga D, Uchida K, Mano T et al. Efficacy of elemental diet on prevention for chemoradiotherapyinduced oral mucositis in patients with oral squamous cell carcinoma. Supportive Care in Cancer 2016; 24 (2): 953-959. doi: 10.1007/s00520-015-2866-7
28. Gussgard AM, Hope AJ, Jokstad A, Tenenbaum H, Wood R. Assessment of cancer therapy-induced oral mucositis using a patient-reported oral mucositis experience questionnaire. PloS One 2014; 9 (3): e91733. doi: 10.1371/journal.pone.0091733
29. Sung L, Tomlinson GA, Greenberg ML, Koren G, Judd P et al. Validation of the oral mucositis assessment scale in pediatric cancer. Pediatric Blood & Cancer 2007; 49 (2): 149-153. doi: 10.1038/bjc.2013.618
30. Nagarajan K. Chemo-radiotherapy induced oral mucositis during IMRT for head and neck cancer-an assessment. Medicina Oral Patologia Y Oral Cirugia Bucal 2015; 20 (3): e273. doi: 10.4317/medoral.20126